Turner syndrome is one of the most common genetic disorders, affecting one in 2,000-2,500 live-born girls. In order to provide appropriate healthcare, a multi-disciplinary team of closely cooperating endocrinologists, gynaecologists, geneticists, cardiologists, otolaryngologists, fertility specialists, psychologists, nurse educators and social workers is needed.
1
TS patients require multi-disciplinary and long-term medical healthcare. At various ages, different medical problems are the focus of treatment. Short stature is diagnosed in approximately 95 % of TS patients. Without medical intervention, the final height is 20 cm below normal range. 2 Haploinsufficiency of short stature homebox (SHOX) gene is responsible for short stature and other TS-associated skeletal anomalies.
The efficacy of recombinant growth hormone (GH) therapy was first confirmed by a Canadian study. 3 Positive predictive markers of good response to GH include tall height at therapy onset, taller parents, better first-year responsiveness to GH, higher GH doses and longer time of therapy; the optimal age for the start of GH treatment has not as yet been established. Bone age more than 14 years and/or growth velocity less than 2 cm/year indicate the end of growth-promoting therapy. In some older patients (~9 years) with very poor prognosis of final height, the addition of a low dose of oxandrolone (non-aromatisable anabolic steroid) should be considered. 4 The addition of Ox to GH treatment may increase adult height by even more than 4 cm. 5 The lack of pubertal growth spurt is one of the causes of short stature in TS patients. Gonadal dysgenesis is diagnosed in most TS patients; however, more than 30 % of girls with TS present some symptoms of puberty (especially patients with the 45,X/46,XX karyotype). If growth-promoting therapy is initiated at a younger age, puberty induction can be started earlier in order to mimic physiology. The mean age for oestrogen therapy is 12 to 14 but low-dose treatment can be started even in younger girls. 1 Puberty should be initiated by using low-dose transdermal oestrogens, although the optimal formulation, dosage and route of administration are still under 
